Effect of Nigella sativa extraction supplement in benign prostatic hyperplasia

Evaluation of the effect of Nigella sativa extraction supplement for benign prostatic hyperplasia patients treatment: A randomized placebo-controlled clinical trial

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20201108049311N4

Enrollment

Registered

2021-09-06

Start date

2021-08-23

Completion date

Unknown

Last updated

2021-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign prostatic hyperplasia. Benign neoplasm of prostate

Interventions

Intervention 1: Intervention group: capsule recipients containing 75 milligram hydroalcoholic Nigella sativa extraction of Zahravi pharmatheutical company in the form of two capsules per meal (three t

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Having benign prostate hyperplasia with or without lower urinary tract symptoms Eligible to participate in the study

Exclusion criteria

Exclusion criteria: Presence of possible allergy to Nigella sativa extraction supplement

Design outcomes

Primary

Measure	Time frame
Evaluation of urinary problems. Timepoint: At first, 2, 4 and 8 weeks after the drug intervention. Method of measurement: Designed IPSS questionnaire.;Measuring the prostatic volume. Timepoint: At first, 2, 4 and 8 weeks after the drug intervention. Method of measurement: Evaluation of ultrasound results.	—

Secondary

Measure	Time frame
Measuring the remained urine volume. Timepoint: At first, 2, 4 and 8 weeks after the drug intervention. Method of measurement: Evaluation of ultrasound results.;Evaluating prostatic specific antigen (PSA) level. Timepoint: At first, 2, 4 and 8 weeks after the drug intervention. Method of measurement: ELISA test from blood samples.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Mohammadreza Ardalan

Tabriz University of Medical Sciences

ardalan34@yahoo.com+98 41 3337 3992

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026